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Abstract—Metabolites can serve as biomarkers and their iden-
tification has significant importance in the study of biochemical
reaction and signalling networks. Incorporating metabolic and
gene expression data to reveal biochemical networks is a consider-
able challenge, which attracts a lot of attention in recent research.
In this paper, we propose a promising approach to identify
metabolic biomarkers through integrating available biomedical
data and disease-specific gene expression data. A Linear Pro-
gramming (LP) based method is then utilized to determine flux
variability intervals, therefore enabling the analysis of significant
metabolic reactions. A statistical approach is also presented to
uncover these metabolites. The identified metabolites are then
verified by comparing with the results in the existing literature.
The proposed approach here can also be applied to the discovery
of potential novel biomarkers.
I. INTRODUCTION
Human diseases, in particular metabolic diseases, can be
directly caused by the lack of essential metabolites. Metabolic
diseases profiling is a promising technique to uncover the
mechanism of disease-metabolite associations. Research in the
past decades mainly focused on the analysis of metabolic
networks [1], [2], [3]. Models for investigating large-scale
metabolic networks with few parameters [4], [5] in constraint
outperform other quantitative approaches. Three types of infor-
mation have been used to describe a metabolic network. One of
them is stoichiometry, which is used to depict the quantitative
associations among reactants and products in all the involved
reactions. Another part consists of enzymes corresponding to
each reaction in the network. The last part is the flux capacity
of each reaction. Here we employ Human Recon 1, one of the
two independently developed human metabolic networks [6],
[7] in our study. Within this genome-scale human metabolic
network, there are in total 3742 reactions, involving 2766
metabolites and 1905 genes.
Flux balance analysis [8] is a traditional constraint-based
approach to predict flux distribution. Taking into account the
flux capacity, stoichiometry and thermodynamics, a number of
constraints can be constructed so as to narrow down the range
of flux. In [9], a list of important metabolic reactions was
identified utilizing flux balance analysis. This demonstrates
the importance of understanding metabolic reactions. Drug
targets, in particular enzymes, are selected to reduce abnormal
metabolites by formulating an optimal combination problem in
enzyme combination on metabolic networks [10], [11]. In [12],
a drug-reaction network was constructed to predict enzyme
targets by profiling human metabolic reactions in NCI-60 cell
lines. Here we develop a computational method to identify
metabolic biomarkers by profiling human metabolic reactions
with the integration of the disease-specific gene-expression
data. We remark that metabolic biomarkers are metabolites
demonstrating consistent variation in concentration in disease
state and can be useful for diagnostic purpose. Metabolomics
exhibits a series of superiorities for diagnostic purpose [13]. As
a safe evaluator for drug candidates and an efficient diagnostic
tool, metabolomics will therefore have an important role.
A Linear Programming (LP) based approach is efficient for
determining the optimal flux distributions under a series of
metabolic constraints. However, multiple solutions might exist
which means that multiple optimal solutions may exist in the
flux space with the same objective value. We address this issue
by calculating both the lower and the upper bounds of fluxes in
each reaction within the metabolic networks [17]. The obtained
flux profiles are then used to determine the significance of
metabolic reactions. The corresponding boundary metabolites
involved in the highly significant reactions are identified as
final metabolic biomarkers. In this paper, we propose simple s-
tatistical criteria to select significant metabolites. Furthermore,
in our study, we consider two diseases: Diabetes and Obesity.
Diabetes Mellitus, Diabetes for simplicity, is a group of
metabolic diseases which are among the major human mal-
nutrition diseases. A possible way to prevent the disease is
risk assessment. Metabolic profiling as an unbiased technique
that can possibly contribute to the identification of high-risk
candidates and reduce related costs [14]. Obesity increases
the likelihood of various diseases, particularly heart disease
and type II Diabetes. It is also our interest to understand the
mechanism of Obesity so as to develop a potential medical
treatment.
In this paper, we integrate disease-specific (two diseases:
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Diabetes and Obesity are considered) gene expression data
with human metabolic network to analyze the flux profiles of
each reaction within the network. Metabolic biomarkers are
identified to hold potential applications for disease diagnosis.
In the following section, we will introduce the framework
of reaction profiling for metabolite biomarker discovery. Two
diseases are considered where two sets of potential biomarkers
are identified. The validity of our proposed approach will be
further discussed in the conclusion of the paper.
II. MATERIALS AND METHODOLOGY
In this section, we introduce our proposed method for
metabolite biomarker discovery which is different from the
popular method for their discovery, see for instance [13].
A. Materials
Two types of data are adopted in this paper. The first type
is gene expression data of two diseases: (i) Diabetes and
(ii) Obesity. The gene expression data is publicly available
in GEO datasets in the NCBI data bank [36]. In Diabetes
gene expression data, there are 12558 genes involved. The
expression value is measured as log2 transformed signal.
The platform to process these data is Platform GPL8300. In
Obesity gene expression data, there are 54675 genes involved.
The expression value is measured as log2 transformed signal.
The platform to process these data is Platform GPL570. The
second type of data is genome-scale human metabolic network
reconstructed by Duarte et al [7]. It can be downloaded from
BiGG database [37], where 3742 reactions are included, with
2766 metabolites and 1905 corresponding genes.
B. Methodology
We introduce the procedures for integrating gene expression
data and the human metabolic network. There are three major
steps from the preparations to the LP model construction and
then to the biomarker determination.
1) Expression Levels in Reactions: Gene expression data
in disease/normal samples is used to determine the expression
levels in reactions. Because for each reaction the related genes
are involved, it is necessary to determine their expression lev-
els. In the gene expression data, expression value is measured
as log2 transformed signal value. Here we first transform them
to binary variables with 0 indicating lowly expressed and 1 for
highly expressed genes. The normalization scheme is given as
follows:
New Signal =
signal− µsignal
σsignal
.
Here µsignal is the average signal value, σsignal is the standard
deviation of the signal vector. After the transformation, genes
having negative New Signal values are defined as lowly ex-
pressed, otherwise they are considered to be highly expressed.
We then use gene expression data to define gene expression
level and determine also the expression levels for the reactions.
In each reaction, there can be 0, 1 or a few genes participating
in the reaction procedure. Those highly expressed reactions
are defined if all the participating genes are highly expressed,
otherwise, we define the reactions to be lowly expressed.
In this way, we make use of the gene expression values in
the disease/normal sample to identify highly/lowly expressed
reactions. Therefore, expression levels in some reactions in
the disease sample will be different from those in the normal
sample.
2) Flux Profiles with Linear Programming:
• The Linear Programming (LP) Model:
Integration of tissue-specific gene and protein expression
data with human metabolic network results in a Mixed
Integer Linear Programming (MILP) model [15] to pre-
dict human tissue-specific metabolic behavior. The MILP
model can be described in the following:
max
y+
i
,y−
i
,v
{∑
i∈RH
(y+i + y
−
i ) +
∑
i∈RL
y+i
}

S · v = 0
vmin ≤ v ≤ vmax
vi + y
+
i (vmin,i − ) ≥ vmin,i, i ∈ RH
vi + y
−
i (vmax,i + ) ≤ vmax,i, i ∈ RH
vmin,i(1− y+i ) ≤ vi ≤ vmax,i(1− y+i ), i ∈ RL
y+i , y
−
i ∈ {0, 1}.
Here v is the flux of all the reactions, and S is
the stoichiometric matrix describing the quantitative
relationships among the products and the reactants in the
reactions. The parameter  is the flux threshold, and it is
chosen to be 1, see for instance [12]. Here RH and RL
are respectively the sets of highly and lowly expressed
reactions. The binary variables y+i and y
−
i represent
if reaction i is active or inactive respectively. In our
method, we relax the binary variables to continuous
variables in [0, 1], i.e., we replace the last constraint by
0 ≤ y+i ≤ 1 and 0 ≤ y−i ≤ 1. Thus the MILP model is
relaxed to a LP model. In the LP model, y+i and y
−
i can
also be interpreted as the likelihoods for reaction i to be
active. More importantly, the LP model is much easier
to handle when compared to the MILP model.
• Flux Profiles in Disease / Normal Sample:
Multiple optimal solutions exist for the same objective
function, meaning that we have multiple feasible
solutions satisfying the same constraints in the model
[16]. The emphasis of investigating the multiplicity of
solutions is to find the lower bound and upper bound
for each flux in the corresponding reactions satisfying
the constraints and ensuring the optimal objective value.
And it has been shown that one can determine all the
flux ranges through solving a series of LP problems
[17]. Hence one can use the obtained objective value
to further explore the flux ranges in reactions through
solving a list of LP problems.
• Identification of Significant Reactions:
Investigation of alternate optimal solutions provides us
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TABLE I
SIGNIFICANT REACTIONS FOR DIABETES
Index Reactions
1238 “[e]:ac ⇀↽ ac”
1951 “gcald[c]+h2o[c]+nad[c] → glyclt[c]+(2)h[c]+nadh[c]”
2297 “eandrstrn[r]+h[r]+nadph[r]→ andrstandn[r]+h2o[r]+nadp[r]”
2357 “atp[c]+xylu-D[c]→ adp[c]+h[c]+xu1p-D[c]”
2700 “dcdp[c]+h2o[c] → dcmp[c]+h[c]+pi[c]”
with four flux profiles: lower bound of flux vector in
disease sample, upper bound of flux vector in disease
sample, lower bound of flux vector in the normal sample
and upper bound of flux vector in normal sample.
Alternatively, we obtain two vectors of intervals for both
the disease and the normal samples respectively. We then
identify and label those reactions as significant reactions
when there is no overlapping between the two intervals.
• Significant Metabolite Discovery:
For a specific disease, we consider both control and
disease samples. This means that we can identify two
sets of reaction markers. Finally reaction markers are
determined if the corresponding flux ranges in disease and
normal samples have no overlap. Metabolite Biomarkers
are then selected as the boundary metabolites in the
significant reactions.
Comparing to the well known model using the human
metabolic network to predict metabolic biomarkers of human
inborn errors of metabolism [13], our model takes into con-
sideration more realistic constraints. Firstly, the genome-scale
human metabolic network we utilize here, consists of 1905
boundary metabolites and 3742 reactions in total. Secondly,
we integrate gene expression data in normal and disease state
to mark highly and lowly expressed reactions. Without forcing
the reactions to be active in normal state or inactive in disease
state, we use a probability measure for the reaction to be
active or inactive instead. We use two pairs of gene expression
data in both healthy and disease status and consider the
overlap of the discovered metabolic biomarkers. For solution
of the LP problems involved we use a large-scale optimization
method which is based on LIPSOL (Linear Interior Point
Solver [35]) in MATLAB R2008a on a vista machine. These
characteristics of our approach would contribute to discover
metabolic biomarkers in a more significant way.
III. RESULTS AND DISCUSSIONS
In this section, we discuss some of our findings. In the case
of Diabetes, after comparing the significant reactions in two
pairs of samples in disease and normal state, we have filtered
out five reactions, the indices of which are listed in Table I.
Index i means the ith reaction in the metabolic network. On
the right-hand side of the index, there is a description of the
reaction. We also list all the participating genes in these five
reactions in Table II.
TABLE II
SIGNIFICANT GENES FOR DIABETES
Reactions Index Genes
1238 “NONE”
1951 “ALDH1A1” “ALDH1A2” “ALDH1A3” “ALD-
H3A1” “ALDH3A2” “ALDH3B1” “ALDH3B2”
“ALDH7A1” “ALDH9A1”
2297 “HSD3B2”
2357 “KHK”
2700 “NONE”
TABLE III
SIGNIFICANT REACTIONS FOR OBESITY
Index Reactions
158 “4abut[m]+akg[m]⇀↽glu-L[m]+sucsal[m]”
248 “ac[m]+atp[m]+coa[m]→ accoa[m]+amp[m]+ppi[m]”
582 “apoC-Lys[c]+btamp[c]→ amp[c]+apoC-Lys btn[c]+h[c]”
1506 “[e]:pydam ⇀↽pydam”
3682 “(2)na1[e]+uri[e]→(2)na1[c]+uri[c]”
TABLE IV
SIGNIFICANT GENES FOR OBESITY
Reactions Index Genes
158 “ABAT”
248 “ACAS2L”
582 “HLCS”
1506 “NONE”
3682 “SLC28A3”
For the case of Obesity, after comparing the significant
reactions in two pairs of samples in disease and normal status,
we obtained five significant reactions as well, with the index
of these reactions listed in Table III. Index i means the
ith reaction in the genome-scale human metabolic network.
The right column of the table provides a description of the
reactions. All the participating genes in these five reactions
are listed in Table IV.
The symbol “⇀↽” means the reaction is reversible and
“→” means the reaction is one-way and irreversible. The
number inside the parentheses (.) is the quantity of
the metabolite. For example, in Table II, Reaction 1951,
we need “gcald[c]:h2o[c]:nad[c]=1:1:1” to produce “gly-
clt[c]:h[c]:nadh[c]=1:2:1” products. In the associated genes,
’NONE’ means that no gene was involved in the reaction.
Others like “SLC28A3” and “HLCS” are the gene symbols.
From the perspective of genes, we have identified 11 signifi-
cant genes involved in Diabetes in Table II. Here the “ALDH”
gene and its variants are Aldehyde dehydrogenase. In [18],
experiments have shown that “ALDH” activity is related to
the increasing risk of large vessel disease in Diabetes. And in
a clinical study on Diabetes [19], researchers also have found
that regardless of alcohol consumption, the ALDH2.487Lys
allele was related to the decreasing prevalence odds of type
II Diabetes. It has been shown that direct intra-pancreatic
delivery of high aldehyde dehydrogenase (ALDH) [20] activity
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can be a potential viable strategy for Diabetes. “HSD3B2”
is found highly expressed with regulation of FXR (farnesoid
X receptor) where FXR agonists are emerging therapeutic
treatment of Diabetes [21]. The KHK gene encodes two
enzyme isoforms with distinctive substrate preferences. The
value of KHK as a pharmacological target needs testing [22],
but can be a potential biomarker in Diabetes treatment. For
the case of Obesity, one of the identified genes is “ABAT”.
In Gastroesophageal reflux disease (GERD), Obesity patients
have a high risk of acquiring the disease [23]. Results show
that ABAT is a genetic risk factor for GERD, which strength-
ens the significance of this gene in Obesity [24]. “ACAS2L” is
a known Obesity candidate gene [25] and Obesity is a proved
cardiovascular disease risk factor [26]. As a nucleoside trans-
porter regulating multiple cellular processes, “SLC28A3” was
identified to have significant association with Anthracycline-
induced cardiotoxicity (ACT) [27]. This strongly suggests
the important role of “SLC28A3”. For “HLCS”, its official
name is “holocarboxylase synthetase (biotin-(proprionyl-CoA-
carboxylase (ATP-hydrolysing)) ligase)”. A lack of holocar-
boxylase synthetase activity may result in breathing problems
and other characteristic signs, influencing regulation of genes
for normal development.
Regarding the metabolites related Diabetes, “ac[e]” as an
inhibitor, is very useful for patients in clinical trials, see for
instance [29]. Both “nadph” and “nadp” are important in l-
xylulose which is intensively used in Diabetes diagnosis. And
l-xylulose is obtained by “nadph” and ‘nad’ reduction with “d-
xylulose” [28]. The name of Reaction 1951 is Glycolaldehyde
dehydrogenase. It has been shown that glycolaldehyde has
a significant role in the development of diabetic cardiomy-
opathy [30]. And “pi” in reaction 2700 is a key component
in the disturbance of Diabetes [31]. While in Obesity, 4-
aminobutyrate transaminase (ABAT) has demonstrated the
importance in Obesity [24]. Reaction 248 has the name Acyl
CoA synthetase. One of the related gene Acyl CoA synthetase5
(ACSL5) has an important role in fatty acid metabolism [32].
Reaction 582 has related gene HLCS, the role of which needs
to be further investigated. And pyridoxamine in reaction 1506
potentially will be a new therapeutic target to improve insulin
resistance in Diabetes with Obesity [33]. Uridine transport
is the name of Reaction 3682. From the role of Uridine
Adenosine Tetraphosphate in the Vascular System [34], one
may find some new directions for the Obesity treatment.
IV. CONCLUDING REMARKS
In this paper, we proposed a computational method to
select significant genes and metabolites involved in specific
metabolic diseases. A Linear Programming (LP) based strategy
is used to obtain flux profiles in both the disease and normal
samples. Gene expression data of two pairs of samples in
both disease and normal states helps in discovering genes and
metabolites which can be potential biomarkers. The integration
of gene expression levels with genome-scale human metabolic
network data provides a new way for systematically analyzing
potential biomarkers.
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